

MD7005/MD7255 - Advanced Injectable Therapies

View Online



Advanced Injectable Therapies

Ajikumar B Aryangat and John E Gerich (2010) 'Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk', *Vascular Health and Risk Management*, 6. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860446/>.

Anderson, B., Funnell, M., and American Diabetes Association (2005) *The art of empowerment: stories and strategies for diabetes educators*. 2nd ed. Alexandria, Va: American Diabetes Association.

Ashwell, S.G. et al. (2006) 'Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes', *Diabetic Medicine*, 23(3), pp. 285–292. Available at: <https://doi.org/10.1111/j.1464-5491.2005.01781.x>.

Bergenstal, R.M. et al. (2010) 'Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes', *New England Journal of Medicine*, 363(4), pp. 311–320. Available at: <https://doi.org/10.1056/NEJMoa1002853>.

Bolinder, J. et al. (2016) 'Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial', *The Lancet*, 388(10057), pp. 2254–2263. Available at: [https://doi.org/10.1016/S0140-6736\(16\)31535-5](https://doi.org/10.1016/S0140-6736(16)31535-5).

Bretzel, R.G. et al. (2008) 'Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial', *The Lancet*, 371(9618), pp. 1073–1084. Available at: [https://doi.org/10.1016/S0140-6736\(08\)60485-7](https://doi.org/10.1016/S0140-6736(08)60485-7).

Buse, J.B. et al. (2011) 'Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes', *Annals of Internal Medicine*, 154(2). Available at: <https://doi.org/10.7326/0003-4819-154-2-201101180-00300>.

Carver, C. (2006) 'Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes', *The Diabetes Educator*, 32(6), pp. 910–917. Available at: <https://doi.org/10.1177/0145721706294259>.

Crasto, W. et al. (2009) 'Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus', *Postgraduate Medical Journal*, 85(1002), pp. 219–222. Available at: <https://doi.org/10.1136/pgmj.2008.073379>.

Daly, H. et al. (2015) 'Development of a self-management education module for those with type 2 diabetes on injectable therapies', *Practical Diabetes*, 32(8), pp. 305–310a. Available

at: <https://doi.org/10.1002/pdi.1979>.

Davies, M. et al. (2005) 'Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine', *Diabetes Care*, 28(6), pp. 1282–1288. Available at: <https://doi.org/10.2337/diacare.28.6.1282>.

Davies, M.J. et al. (2009a) 'Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study', *Diabetes, Obesity and Metabolism*, 11(12), pp. 1153–1162. Available at: <https://doi.org/10.1111/j.1463-1326.2009.01154.x>.

Davies, M.J. et al. (2009b) 'Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study', *Diabetes, Obesity and Metabolism*, 11(12), pp. 1153–1162. Available at: <https://doi.org/10.1111/j.1463-1326.2009.01154.x>.

Davies, M.J. et al. (2017) 'Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents', *Diabetes, Obesity and Metabolism* [Preprint]. Available at: <https://doi.org/10.1111/dom.12980>.

Diamant, M. et al. (2010) 'Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial', *The Lancet*, 375(9733), pp. 2234–2243. Available at: [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0).

Evans, M. et al. (2011) 'A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations', *Diabetes, Obesity and Metabolism*, 13(8), pp. 677–684. Available at: <https://doi.org/10.1111/j.1463-1326.2011.01395.x>.

Frandsen, C.S.S. and Madsbad, S. (2014) 'Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review', *Diabetic Medicine*, 31(11), pp. 1293–1300. Available at: <https://doi.org/10.1111/dme.12561>.

Funnell, M.M. (2007) 'Overcoming Barriers to the Initiation of Insulin Therapy', *Clinical Diabetes*, 25(1), pp. 36–38. Available at: <https://doi.org/10.2337/diaclin.25.1.36>.

Garber, A.J. et al. (2006) 'Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)', *Diabetes, Obesity and Metabolism*, 8(1), pp. 58–66. Available at: <https://doi.org/10.1111/j.1463-1326.2005.00563.x>.

Garber, A.J. et al. (2007) 'Premixed insulin treatment for type 2 diabetes: analogue or human?', *Diabetes, Obesity and Metabolism*, 9(5), pp. 630–639. Available at: <https://doi.org/10.1111/j.1463-1326.2006.00654.x>.

- Gough, S.C.L. (2007) 'A review of human and analogue insulin trials', *Diabetes Research and Clinical Practice*, 77(1), pp. 1–15. Available at: <https://doi.org/10.1016/j.diabres.2006.10.015>.
- Gough, S.C.L. et al. (2013) 'Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes', *Diabetes Care*, 36(9), pp. 2536–2542. Available at: <https://doi.org/10.2337/dc12-2329>.
- Gururaj Setty, S. et al. (2016a) 'New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes', *Postgraduate Medical Journal*, 92(1085), pp. 152–164. Available at: <https://doi.org/10.1136/postgradmedj-2015-133716>.
- Gururaj Setty, S. et al. (2016b) 'New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes', *Postgraduate Medical Journal*, 92(1085), pp. 152–164. Available at: <https://doi.org/10.1136/postgradmedj-2015-133716>.
- Heller, S.R. et al. (2004) 'Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes', *Diabetic Medicine*, 21(7), pp. 769–775. Available at: <https://doi.org/10.1111/j.1464-5491.2004.01244.x>.
- Hermansen, K. et al. (2006) 'A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes', *Diabetes Care*, 29(6), pp. 1269–1274. Available at: <https://doi.org/10.2337/dc05-1365>.
- Hirsch, I.B. et al. (2014a) 'Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy', *Diabetes, Obesity and Metabolism*, 16(3), pp. 206–214. Available at: <https://doi.org/10.1111/dom.12136>.
- Hirsch, I.B. et al. (2014b) 'Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy', *Diabetes, Obesity and Metabolism*, 16(3), pp. 206–214. Available at: <https://doi.org/10.1111/dom.12136>.
- Hirsch, I.B. et al. (2017) 'Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1)', *Diabetic Medicine*, 34(2), pp. 167–173. Available at: <https://doi.org/10.1111/dme.13068>.
- Holman, R.R. et al. (2007) 'Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes', *New England Journal of Medicine*, 357(17), pp. 1716–1730. Available at: <https://doi.org/10.1056/NEJMoa075392>.
- Holman, R.R. and Turner, R.C. (1985) 'A Practical Guide to Basal and Prandial Insulin Therapy', *Diabetic Medicine*, 2(1), pp. 45–53. Available at: <https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>.

Home, P.D. (2012) 'The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences', *Diabetes, Obesity and Metabolism*, 14(9), pp. 780–788. Available at: <https://doi.org/10.1111/j.1463-1326.2012.01580.x>.

Horvath, K. et al. (1996a) 'Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus', in *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd. Available at: <https://doi.org/10.1002/14651858.CD005613.pub3>.

Horvath, K. et al. (1996b) 'Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus', in *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd. Available at: <https://doi.org/10.1002/14651858.CD005613.pub3>.

Htike, Z.Z. et al. (2017) 'Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis', *Diabetes, Obesity and Metabolism* [Preprint]. Available at: <https://doi.org/10.1111/dom.12849>.

Inzucchi, S.E. et al. (2015) 'Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes', *Diabetes Care*, 38(1), pp. 140–149. Available at: <https://doi.org/10.2337/dc14-2441>.

Ismail-Beigi, F. (2012) 'Glycemic Management of Type 2 Diabetes Mellitus', *New England Journal of Medicine*, 366(14), pp. 1319–1327. Available at: <https://doi.org/10.1056/NEJMcp1013127>.

June James (no date) 'Safety and insulin: implementation of national guidance at a local level', *Journal of diabetes nursing*. [Preprint]. Available at: http://le-primo.hosted.exlibrisgroup.com/primo_library/libweb/action/openurl?ctx=&isServicesPage=true&rft.jtitle=Journal+of+Diabetes+Nursing&rft.aufirst=June∓dsnt=2&url_ctx_fmt=null&vid=44UOLE_services_page&rft.aulast=James&institution=44UOLE&url_ver=Z39.88-2004&rft.atitle=Safety+and+insulin%3A+implementation+of+national+guidance+at+a+local+level&dstmp=1488893669239&fromLogin=true.

Khunti, K. et al. (2015) 'Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study', *Diabetes Care*, 38(2), pp. 316–322. Available at: <https://doi.org/10.2337/dc14-0920>.

L. Luzi (1989) 'Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans', *American Journal of Physiology - Endocrinology and Metabolism*, 257(2), pp. E241–E246. Available at: <http://ajpendo.physiology.org/content/257/2/E241>.

Leelarathna, L. et al. (2017) 'Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes', *Diabetic Medicine*, 34(10), pp. 1372–1379. Available at: <https://doi.org/10.1111/dme.13412>.

Luc JC van Loon (2000) 'Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate', *The American Journal of Clinical Nutrition*, 72(1), pp. 96–105. Available at: <http://ajcn.nutrition.org/content/72/1/96.full>.

MacKinnon, M. (2002) Providing diabetes care in general practice: a practical guide to integrated care. 4th ed. London: Class. Available at: <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=581376>.

Mäkimattila, S., Nikkilä, K. and Yki-Järvinen, H. (1999) 'Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus', *Diabetologia*, 42(4), pp. 406–412. Available at: <https://doi.org/10.1007/s001250051172>.

Malmberg, K. (1997) 'Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus', *BMJ*, 314(7093), pp. 1512–1512. Available at: <https://doi.org/10.1136/bmj.314.7093.1512>.

Marre, M. et al. (2009) 'Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)', *Diabetic Medicine*, 26(3), pp. 268–278. Available at: <https://doi.org/10.1111/j.1464-5491.2009.02666.x>.

Marso, S.P. et al. (2017) 'Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes', *New England Journal of Medicine* [Preprint]. Available at: <https://doi.org/10.1056/NEJMoa1615692>.

Menting, J.G. et al. (2013) 'How insulin engages its primary binding site on the insulin receptor', *Nature*, 493(7431), pp. 241–245. Available at: <https://doi.org/10.1038/nature11781>.

Nathan, D.M. et al. (2006) 'Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes', *Diabetes Care*, 29(8), pp. 1963–1972. Available at: <https://doi.org/10.2337/dc06-9912>.

Nauck, M. (2016) 'Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors', *Diabetes, Obesity and Metabolism*, 18(3), pp. 203–216. Available at: <https://doi.org/10.1111/dom.12591>.

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes (no date). Available at: <http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>.

Pickup, J.C., Reznik, Y. and Sutton, A.J. (2017) 'Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials', *Diabetes Care*, 40(5), pp. 715–722. Available at: <https://doi.org/10.2337/dc16-2201>.

'Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes' (4AD). Available at: <https://www.youtube.com/watch?v=AhhWTmEFuag>.

Raccah, D., Huet, D., Dib, A, et al. (2017) 'Review of basal-plus insulin regimen options for

simpler insulin intensification in people with Type 2 diabetes mellitus', *Diabetic Medicine* [Preprint]. Available at: <https://doi.org/10.1111/dme.13390>.

Raccah, D., Huet, D., Dib, A., et al. (2017) 'Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus', *Diabetic Medicine*, 34(9), pp. 1193–1204. Available at: <https://doi.org/10.1111/dme.13390>.

Raskin, P. et al. (2005) 'Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs', *Diabetes Care*, 28(2), pp. 260–265. Available at: <https://doi.org/10.2337/diacare.28.2.260>.

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI (no date). Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18715200>.

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein (2016) *Textbook of Diabetes*. John Wiley & Sons, Incorporated. Available at: <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056&query=#>.

Richter, B. and Neises, G. (1996) "'Human" insulin versus animal insulin in people with diabetes mellitus', in *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd. Available at: <https://doi.org/10.1002/14651858.CD003816.pub2>.

Riddle, M.C. et al. (2013) 'Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin', *Diabetes Care*, 36(9), pp. 2489–2496. Available at: <https://doi.org/10.2337/dc12-2454>.

Rodbard, H.W. et al. (2017) 'Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial', *Diabetic Medicine*, 34(2), pp. 189–196. Available at: <https://doi.org/10.1111/dme.13256>.

Rorsman, P. and Renström, E. (2003) 'Insulin granule dynamics in pancreatic beta cells', *Diabetologia*, 46(8), pp. 1029–1045. Available at: <https://doi.org/10.1007/s00125-003-1153-1>.

Rosenstock, J. et al. (2008) 'A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes', *Diabetologia*, 51(3), pp. 408–416. Available at: <https://doi.org/10.1007/s00125-007-0911-x>.

Rosenstock, J. et al. (2013) 'Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)', *Diabetes Care*, 36(10), pp. 2945–2951. Available at: <https://doi.org/10.2337/dc12-2709>.

Rosenstock, J. et al. (2014) 'Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes', *Diabetes Care*, 37(7), pp. 1815–1823. Available at: <https://doi.org/10.2337/dc13-3055>.

Sharon Allard, Caroline Butler, Sue Cradock, Heather Daly, Jemma Edwards, Elizabeth Gilbert (2010) 'Using Conversation Maps in practice: the UK experience', *Journal of Diabetes Nursing*, 14(1). Available at:

<http://go.galegroup.com/ps/i.do?id=GALE|A245106172&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=fe5329820c5da4ed2dd0a88a5ced5962>.

Srinivasan, B.T. et al. (2008) 'Recent advances in the management of type 2 diabetes mellitus: a review', *Postgraduate Medical Journal*, 84(996), pp. 524-531. Available at: <https://doi.org/10.1136/pgmj.2008.067918>.

Srinivasan, B.T. and Davies, M. (2014) 'Glycaemic management of type 2 diabetes', *Medicine*, 42(12), pp. 711-717. Available at: <https://doi.org/10.1016/j.mpmed.2014.09.011>.

Swinnen, S.G. et al. (1996) 'Insulin detemir versus insulin glargine for type 2 diabetes mellitus', in *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd. Available at: <https://doi.org/10.1002/14651858.CD006383.pub2>.

Villani, M., de Courten, B. and Zoungas, S. (2017) 'Emergency treatment of hypoglycaemia: a guideline and evidence review', *Diabetic Medicine*, 34(9), pp. 1205-1211. Available at: <https://doi.org/10.1111/dme.13379>.

Wahren, J. and Kallas, A. (2012) 'Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes?', *Diabetes*, 61(9), pp. 2228-2229. Available at: <https://doi.org/10.2337/db12-0664>.

Walker, R.A., Rodgers, J., and Diabetes UK. (2010) *Diabetes: a practical guide to managing your health*. Fully revised and updated. London: Dorling Kindersley.

Wang, W. et al. (2017) 'Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis', *Diabetes Therapy* [Preprint]. Available at: <https://doi.org/10.1007/s13300-017-0282-3>.

Yki-Järvinen, H. et al. (2006) 'Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study', *Diabetologia*, 49(3), pp. 442-451. Available at: <https://doi.org/10.1007/s00125-005-0132-0>.

Young, L.A. and Buse, J.B. (2014) 'GLP-1 receptor agonists and basal insulin in type 2 diabetes', *The Lancet*, 384(9961), pp. 2180-2181. Available at: [https://doi.org/10.1016/S0140-6736\(14\)61409-4](https://doi.org/10.1016/S0140-6736(14)61409-4).

Zinman, B. et al. (2011) 'Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial', *The Lancet*, 377(9769), pp. 924-931. Available at: [https://doi.org/10.1016/S0140-6736\(10\)62305-7](https://doi.org/10.1016/S0140-6736(10)62305-7).